China Virus Outbreak: Is The New HMPV Strain Causing An Increase In Encephalitis?

After two cases of Human Metapneumovirus (HMPV) were reported in Bengaluru, India, concerns have been heightened by a surge in infections and hospital admissions in China since late December 2024. While HMPV is not a newly discovered virus-it has been infecting humans globally for over six decades-recent research in China has identified novel lineages within the A2 subtype. These new lineages are associated with mutations in three key proteins. These mutations are thought to enhance the virus's ability to affect the nervous system, making it potentially more dangerous. Symptoms such as dizziness, cognitive difficulties, and even encephalitis have been reported, particularly in vulnerable populations like the young and elderly.

Details of Bengaluru's Two Cases

The two confirmed cases in Bengaluru involve infants admitted to Baptist Hospital with bronchopneumonia. The first case is a 3-month-old female infant who was diagnosed with HMPV during her treatment. After receiving appropriate medical care, she has since been discharged and is recovering well. The second case is an 8-month-old male infant who tested positive for HMPV on January 3, 2025. Unlike the first case, this infant remains under observation as he continues to recover.

Notably, neither of the affected infants has any history of international travel, ruling out the possibility of direct exposure to the outbreaks in China. These cases were identified through routine surveillance conducted by the Indian Council of Medical Research (ICMR) to monitor respiratory illnesses across the country.

Emergence of New Lineages and Associated Risks

The mutations observed in the A2 subtype's protein structure suggest an increased neurotrophic capability of the virus, meaning it could more readily target the nervous system. This has led to more severe symptoms in some cases, including neurological issues and severe complications like encephalitis. The rise in cases underscores the importance of vigilance, further research, and timely medical intervention, especially for at-risk groups such as infants, the elderly, and individuals with weakened immune systems.

Challenges in Diagnosis and Treatment

One of the biggest challenges in managing HMPV is the lack of quick diagnostic tests. Unlike influenza or COVID-19, HMPV isn't easy to identify right away, as testing for it is expensive and slow. This can lead to delays in diagnosis, with some cases being missed or misdiagnosed. While HMPV typically causes mild symptoms that clear up in a week, serious complications can occur in vulnerable individuals, making early diagnosis and better testing a priority.

Preventive Measures and Supportive Care

Healthcare experts warn against trying to diagnose HMPV on your own since its symptoms are similar to other respiratory illnesses. Instead, they recommend supportive care, like staying hydrated, getting plenty of rest, and managing symptoms. To prevent the spread of the virus, it's important to wear masks, practice good hand hygiene, ensure proper ventilation, and avoid crowded places.

At this time, there are no specific antivirals or vaccines for HMPV, so the focus remains on prevention and supportive care to reduce its impact.

The recent changes in the A2 subtype of HMPV show the virus's evolving nature, with the potential for more severe neurological complications. The rising reports of dizziness, cognitive issues, and encephalitis in China have raised global concern.